F/m Emerald Life Sciences Innovation ETF (LFSC) Holdings
LFSC holdings summary
as of Oct 25, 2026- Holdings
- 38 positions listed
- Top 10 weight
- 53.5% of net assets
- Effective holdings
- 25 equal-weight equivalent
- Largest holding
- LIVN 6.92% LivaNova PLC
- Annual turnover
- — of the portfolio traded
All LFSC holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | LIVN | LivaNova PLC | Healthcare | 6.92% | $8.5M | $4.26B | 23.0 |
| 2 | CORT | Corcept Therapeutics Incorporated | Healthcare | 6.07% | $7.4M | $11.91B | 244.8 |
| 3 | TVTX | Travere Therapeutics, Inc. | Healthcare | 5.93% | $7.3M | $4.61B | — |
| 4 | COGT | Cogent Biosciences, Inc. | Healthcare | 5.82% | $7.1M | $5.12B | — |
| 5 | REPL | Replimune Group, Inc. | Healthcare | 5.78% | $7.1M | $1.02B | — |
| 6 | SYRE | Spyre Therapeutics, Inc. | Healthcare | 5.48% | $6.7M | $7.47B | — |
| 7 | GH | Guardant Health, Inc. | Healthcare | 5.06% | $6.2M | $21.28B | — |
| 8 | BLLN | BillionToOne, Inc. | Healthcare | 4.62% | $5.7M | $4.63B | 155.7 |
| 9 | MANE | Veradermics, Incorporated | Healthcare | 4.17% | $5.1M | $4.55B | — |
| 10 | UTHR | United Therapeutics Corporation | Healthcare | 3.67% | $4.5M | $22.87B | 19.1 |
| 11 | MIRM | Mirum Pharmaceuticals, Inc. | Healthcare | 3.52% | $4.3M | $5.20B | — |
| 12 | CYTK | Cytokinetics, Incorporated | Healthcare | 3.21% | $3.9M | $8.61B | — |
| 13 | TMDX | TransMedics Group, Inc. | Healthcare | 3.09% | $3.8M | $2.45B | 18.3 |
| 14 | AXSM | Axsome Therapeutics, Inc. | Healthcare | 2.86% | $3.5M | $8.23B | — |
| 15 | ICUI | ICU Medical, Inc. | Healthcare | 2.71% | $3.3M | $4.08B | 137.0 |
| 16 | VRDN | Viridian Therapeutics, Inc. | Healthcare | 2.54% | $3.1M | $2.16B | — |
| 17 | SVRA | Savara Inc. | Healthcare | 2.40% | $2.9M | $914.3M | — |
| 18 | TRVI | Trevi Therapeutics, Inc. | Healthcare | 2.18% | $2.7M | $1.69B | — |
| 19 | CBLL | CeriBell, Inc | Healthcare | 2.09% | $2.6M | $961.0M | — |
| 20 | TWST | Twist Bioscience Corporation | Healthcare | 2.01% | $2.5M | $8.80B | — |
| 21 | PVLA | Palvella Therapeutics, Inc | Healthcare | 1.79% | $2.2M | $1.73B | — |
| 22 | PRAX | Praxis Precision Medicines, Inc. | Healthcare | 1.71% | $2.1M | $6.75B | — |
| 23 | NKTR | Nektar Therapeutics | Healthcare | 1.69% | $2.1M | $1.22B | — |
| 24 | DNTH | Dianthus Therapeutics, Inc. | Healthcare | 1.50% | $1.8M | $4.03B | — |
| 25 | CRVS | Corvus Pharmaceuticals, Inc. | Healthcare | 1.47% | $1.8M | $800.8M | — |
| 26 | ATEC | Alphatec Holdings, Inc. | Healthcare | 1.36% | $1.7M | $1.62B | — |
| 27 | HNGE | Hinge Health, Inc. | Healthcare | 1.14% | $1.4M | $8.00B | 32.7 |
| 28 | NEO | NeoGenomics, Inc. | Healthcare | 1.12% | $1.4M | $2.14B | — |
| 29 | VCEL | Vericel Corporation | Healthcare | 1.12% | $1.4M | $2.05B | 85.4 |
| 30 | ALMR | Alamar Biosciences, Inc. | Healthcare | 1.10% | $1.3M | $1.75B | — |
| 31 | GMED | Globus Medical, Inc. | Healthcare | 1.10% | $1.3M | $10.30B | 19.7 |
| 32 | RDNT | RadNet, Inc. | Healthcare | 0.91% | $1.1M | $5.41B | — |
| 33 | WAY | Waystar Holding Corp. | Healthcare | 0.77% | $944,202.24 | $5.25B | 39.1 |
| 34 | KRRO | Korro Bio, Inc. | Healthcare | 0.67% | $824,859.78 | $125.0M | — |
| 35 | SENS | Senseonics Holdings, Inc. | Healthcare | 0.44% | $537,898.76 | $410.8M | — |
| 36 | RBIL | F/m Ultrashort Treasury Inflation-Protected Security (TIPS) ETF | Other | 0.44% | $537,041.06 | — | — |
| 37 | WVE | Wave Life Sciences Ltd. | Healthcare | 0.44% | $534,713.03 | $616.8M | — |
| 38 | OBIL | US Treasury 12 Month Bill ETF | Other | 0.10% | $117,014.42 | — | — |
Weights as a percentage of net assets. Value held = weight × net assets ($122.5M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
LFSC sector breakdown
| Sector | Weight | Holdings | Largest |
|---|---|---|---|
| Healthcare | 98.5% | 36 | LIVN, CORT, TVTX |
| Other | 0.5% | 2 | RBIL, OBIL |
Sum of the weights of the holdings in each sector.
LFSC top industries
LFSC overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| IWM | iShares Russell 2000 ETF | 3.1% | 30 of 1,962 | 0.19% |
| VTI | Vanguard Total Stock Market ETF | 0.2% | 34 of 2,941 | 0.03% |
| VXUS | Vanguard Total International Stock ETF | 0.0% | 1 of 8,035 | 0.05% |
| SPY | SPDR S&P 500 ETF | 0.0% | 0 of 502 | 0.09% |
| QQQ | Invesco QQQ ETF | 0.0% | 0 of 101 | 0.17% |
| DIA | SPDR Dow Jones Industrial Average ETF | 0.0% | 0 of 30 | 0.16% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the LFSC portfolio
F/m Emerald Life Sciences Innovation ETF holds 38 positions. The ten largest make up 53.5% of the fund, so it behaves like a portfolio of about 25 equally weighted stocks. The biggest positions are LivaNova PLC (6.92%), Corcept Therapeutics Incorporated (6.07%), Travere Therapeutics, Inc. (5.93%), Cogent Biosciences, Inc. (5.82%), Replimune Group, Inc. (5.78%).
By sector, Healthcare is 98.5%, Other is 0.5%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: LFSC chart, LFSC performance, LFSC overview.
LFSC holdings FAQ
How many holdings does LFSC have?
LFSC holds 38 positions as of October 25, 2026.
What are the top 10 holdings of LFSC?
The ten largest holdings are LivaNova PLC (6.92%), Corcept Therapeutics Incorporated (6.07%), Travere Therapeutics, Inc. (5.93%), Cogent Biosciences, Inc. (5.82%), Replimune Group, Inc. (5.78%), Spyre Therapeutics, Inc. (5.48%), Guardant Health, Inc. (5.06%), BillionToOne, Inc. (4.62%), Veradermics, Incorporated (4.17%), United Therapeutics Corporation (3.67%). Together they are 53.5% of the fund.
What percentage of LFSC is LivaNova PLC?
LivaNova PLC is the largest holding at 6.92% of net assets, about $8.5M of the fund's $122.5M.
How concentrated is LFSC?
The top 10 holdings are 53.5% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) LFSC behaves like a portfolio of about 25 equally weighted stocks.